Coherus BioSciences to Partner with STORM on Development of LOQTORZI/STC-15 Combination for Cancer Treatment.

Coherus BioSciences is partnering with STORM Therapeutics to evaluate the METTL3 inhibitor STC-15 in combination with LOQTORZI for non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and endometrial cancer. The Phase 1b/2 study will assess the safety and efficacy of the combination, with up to 188 patients in the United States. Coherus will provide LOQTORZI, while STORM will sponsor the trial.

Coherus BioSciences, Inc. (CHRS) has entered into a clinical collaboration with STORM Therapeutics Ltd. to evaluate the combination of STC-15, a METTL3 inhibitor, and LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer. The collaboration was announced on May 27, 2025, and patient dosing has already begun in the Phase 1b/2 study [2].

The Phase 1b portion of the study will evaluate the safety and efficacy of the combination therapy, while the Phase 2 portion will focus on expansion cohorts in NSCLC, HNSCC, endometrial cancer, and melanoma, enrolling up to 188 patients in the United States. The trial is sponsored by STORM Therapeutics, with Coherus providing the LOQTORZI compound under the terms of the clinical trial collaboration and supply agreement [1][2].

Under the agreement, Coherus will retain commercial rights to LOQTORZI, while STORM will retain rights to STC-15. This strategic partnership aligns with Coherus' goal of expanding the potential indications for LOQTORZI beyond nasopharyngeal carcinoma (NPC) and leveraging cost-efficient drug supply agreements [2].

Coherus BioSciences is a commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI®, and a promising pipeline that includes two mid-stage clinical candidates targeting various cancers [3]. The company's strategy involves growing sales of LOQTORZI in NPC and advancing the development of new indications for LOQTORZI in combination with both its pipeline candidates and those of its partners [3].

The collaboration between Coherus and STORM is part of Coherus' broader strategy to evaluate LOQTORZI with novel mechanisms in prioritized tumor types, aiming to enhance outcomes for cancer patients [2].

References:
[1] https://www.marketscreener.com/quote/stock/COHERUS-BIOSCIENCES-INC-18460920/news/Coherus-BioSciences-Inc-Announces-Clinical-Collaboration-with-STORM-Therapeutics-to-Evaluate-STC-1-50077551/
[2] https://investors.coherus.com/news-releases/news-release-details/coherus-announces-clinical-collaboration-storm-therapeutics
[3] https://www.globenewswire.com/news-release/2025/05/27/3088627/33333/en/Coherus-Announces-Clinical-Collaboration-with-STORM-Therapeutics-to-Evaluate-STC-15-in-Combination-with-LOQTORZI-toripalimab-tpzi.html